Processos biotecnológicos dependem significativamente das técnicas de separação e purificação utilizadas, para manter boa relação custo-benefício na produção em escala industrial de produtos biotecnológicos com fins comerciais, industriais e terapêuticos. A aplicação do sistema micelar de duas fases aquosas (SMDFA) é proposta como alternativa para purificação de biomoléculas/biopartículas, pois permite sua separação e análise, muitas vezes sem que essas percam sua atividade ou propriedades desejadas. Com essa técnica é possível realizar uma partição seletiva que possibilita altos rendimentos. Esse trabalho destinou-se a estudar o emprego dessa metodologia na extração e purificação de Adenovírus em sistema micelar de duas fases aquosas formado por Triton X-114/Suspensão viral. Os ensaios foram realizados em sistemas de 5 g seguindo um planejamento fatorial completo (23) com 4 pontos centrais. Os fatores estudados foram temperatura de extração, pH da suspensão viral e concentração do tensoativo. Sistemas contendo massas de 3g, 10g e 40g foram avaliados. Foi avaliado o efeito do processo de extração com SMDFA sobre a integridade e infectividade de Adenovírus. Alguns dos parâmetros avaliados no processo foram a recuperação da potência viral (RPv) e a recuperação da potência viral específica (RPvø). Esses dois parâmetros avaliam a inativação do Adenovirus pelo processo de extração e ambos apresentaram melhoras quando comparados com a própria suspensão viral para alguns dos sistemas estudados (i.e RPv:341 % e RPvø 1466 %). Esses resultados indicam que o SMDFA foi capaz de particionar seletivamente as partículas virais infecciosas. De acordo com os resultados do planejamento é possível aumentar ainda mais esses resultados controlando as variáveis concentração de tensoativo, pH da suspensão viral e temperatura de extração. / Biotechnological processes depend significantly on separation and purification techniques used to maintain cost-effective industrial-scale production of biotechnological products for commercial, industrial and therapeutic uses. The application of the aqueous two-phase micelar system (ATPMS) is proposed as an alternative for purification, since it allows the separation and analysis of biomolecules /bioparticles, often without loses of activity or their properties. This allows to perform a selective partition that enables high yields. This work aims to study the use of this methodology in the extraction and purification of adenovirus in micelle aqueous two-phase formed by TritonX-114/Viral suspension. All assays were performed in 5 g systems following a full factorial design (23) with four central points. The studied factors were extraction temperature, pH of the viral suspension and concentration of the surfactant. Systems containing masses of 3g, 10g and 40g were evaluated. Extraction procedure effects over integrity and infectivity of adenovirus were also evaluated. Some of the parameters evaluated in the viral recovery process were viral potency (RPv) and recovery of viral specific potency (RPvø). These two parameters measure the inactivation of Adenovirus by the extraction process and both showed improvement when compared with the viral suspension for some of the systems studied (i.e RPv: 341% and RPvø 1466%). These results show that ATPMS selectively partition the infectious viral particles. According to the results of the experimental design is possible to increase, even further, these results controlling the surfactant concentration, viral suspension pH and temperature of extraction.

Neste trabalho nós estudamos qual seria o impacto da indução de resposta imune a epítopos CD8 subdominantes na imunidade gerada pela vacinação genética. Durante a infecção experimental apenas um epítopo imunodominante presente no antígeno ASP-2 é reconhecido. Já os linfócitos T CD8+ induzidos nos animais vacinados com o gene da ASP-2 são capazes de reconhecer além deste mais dois outros epítopos (subdominantes). A identificação desses epítopos permitiu que estudássemos o papel da resposta imune a epítopos subdominantes na imunidade protetora. Após imunização genética com o gene da ASP-2 mutado, sem resposta para o epítopo dominante, confirmamos que a resposta imune aos epítopos subdomiantes pode contribuir na proteção contra a infecção experimental. Apesar do papel critico dos linfócitos T CD8+ na resposta imune protetora induzida pela vacinação genética do tipo imunização e reforço heterólogo, não se sabe ao certo se após o desafio experimental estes linfócitos T CD8+ necessitam proliferar ou recircular para mediar a imunidade protetora. Nossos resultados desafiam o paradigma de ação das vacinas tradicionais de que a imunidade é dependente da proliferação e não da recircular dos linfócitos T de memória e para mediar a imunidade protetora. / In the present study, we evaluated the impact of the immune response to sub-dominant CD8 epitopes on immunity generated by genetic vaccination. During experimental infection only a single dominant epitope is recognized on the antigen ASP-2. In contrast, the CD8+ T lymphocytes induced in animals genetically vaccinated with ASP-2 recognized, in addition to the dominant epitope, two other epitopes (sub-dominants). The identification of these epitopes allowed us to test the role of immune response to sub-dominant epitopes in protective immunity. After genetic vaccination with ASP-2 mutated gene, without the response to dominant epitope, we concluded that the immune response to the sub-dominant epitopes can be important to protective immunity. In spite of the critical role of CD8+ T lymphocytes in protective immune response induced by genetic vaccination using the heterologous prime-boost regimen, it is unclear whether after the experimental challenge these CD8+ T lymphocytes need to proliferate or recirculate to mediate protective immunity. Our results challenge the paradigm of action of traditional vaccines that immunity is dependent on the proliferation of memory T lymphocytes and that these cells do not need to recirculate.

L’adénovirus possède plusieurs caractéristiques faisant de ce virus un candidat de choix pour la construction de vecteurs utiles dans les études de génomique fonctionnelle. Dans la majorité de ces applications, on a recours à un vecteur adénoviral de première génération délété de sa région E1. L’utilisation de vecteurs adénoviraux comprend deux maillons faibles : la construction du vecteur et la production subséquente de ce dernier. Le développement de méthodes alternatives est donc nécessaire pour renforcer ces deux maillons, permettant ainsi une utilisation étendue de ces vecteurs. Ce développement va s’articuler sur deux axes : l’ingénierie du vecteur de transfert pour la construction de l’adénovirus recombinant et l’ingénierie d’une lignée cellulaire pour la production du vecteur. En utilisant un vecteur de transfert adénoviral co-exprimant, à partir d’un promoteur régulable à la tétracycline, la protéase de l’adénovirus et une protéine de fluorescence verte (GFP) par l’intermédiaire d’un site d’entrée ribosomal interne (IRES), notre groupe a établi que la sélection positive, via l’expression ectopique de la protéase, est un processus efficace pour la création de librairie d’adénovirus recombinants. Par contre, la diversité atteinte dans ce premier système est relativement faible, environ 1 adénovirus recombinant par 1 000 cellules. Le travail effectué dans le cadre de cette thèse vise à construire un nouveau transfert de vecteur dans lequel l’expression de la protéase sera indépendante de celle du transgène permettant ainsi d’optimiser l’expression de la protéase. Ce travail d’optimisation a permis de réduire le phénomène de transcomplémentation du virus parental ce qui a fait grimper la diversité à 1 virus recombinant par 75 cellules. Ce système a été mis à l’épreuve en générerant une librairie adénovirale antisens dirigée contre la GFP. La diversité de cette librairie a été suffisante pour sélectionner un antisens réduisant de 75% l’expression de la GFP. L’amplification de ce vecteur adénoviral de première génération doit se faire dans une lignée cellulaire exprimant la région E1 telle que les cellules 293. Par contre, un adénovirus de première génération se répliquant dans les cellules 293 peut échanger, par recombinaison homologue, son transgène avec la région E1 de la cellule créant ainsi un adénovirus recombinant réplicatif (RCA), compromettant ainsi la pureté des stocks. Notre groupe a déjà breveté une lignée cellulaire A549 (BMAdE1) exprimant la région E1, mais qui ne peut pas recombiner avec le transgène du virus. Par contre, le niveau de réplication de l’adénovirus dans les BMAdE1 est sous-optimal, à peine 15-30% du niveau obtenu dans les cellules 293. Le travail fait dans le cadre de cette thèse a permis de mettre en évidence qu’une expression insuffisante d’E1B-55K était responsable de la mauvaise réplication du virus dans les BMAdE1. Nous avons produit de nouveaux clones à partir de la lignée parentale via une transduction avec un vecteur lentiviral exprimant E1B-55K. Nous avons confirmé que certains clones exprimaient une plus grande quantité d’E1B-55K et que ces clones amplifiaient de manière plus efficace un vecteur adénoviral de première génération. Ce clone a par la suite été adapté à la culture en suspension sans sérum. / The adenovirus has numerous interesting characteristics making this particular virus an ideal candidate for the construction of vector for conducting studies in functional genomics. The vast majority of those applications rely on a so-called “first-generation vector” in which the E1 region is replaced by a transgene. Despite all their advantages, there are 2 weak links associated with first-generation vector: the efficient construction of the actual vector and its production. Therefore, the development of alternative methods for construction and production is necessary to ensure their usefulness. The development will involve 2 axes: the reengineering of the transfer vector for the construction of recombinant adenovirus and the reengineering of the cell line capable of producing the vector. Using a transfer vector co-expressing the adenoviral protease (PS) gene and GFP by using an IRES under the control of a tetracycline-regulated promoter, our laboratory previously established the proof of concept that positive selection of recombinant adenovirus through ectopic expression of the PS gene was an efficient approach to generate adenoviral libraries. However, the diversity achieved was quite low, around 1 recombinant adenovirus per 1,000 cells. The goal of this thesis was to design a new transfer vector in which the PS expression was independent from the expression of the transgene in order to be able to optimize its expression independently. We also improved library diversity by lowering the amount of PS in order to reduce the the trans-complementation from the transfer vector. Using this method, at least 1 recombinant adenovirus per 75 cells was generated with 100% of the plaques being recombinant. This system was successfully used to generate an antisense library targeting GFP. The diversity of the library was high enough to allow the selection of an antisense that inhibited 75% of GFP expression. Amplification of those first-generation recombinant adenoviruses must take place in an E1-expressing cell such as 293 cells. However, when replicating in 293 cells, the recombinant adenovirus can exchange their transgene with the E1 region of the cell by homologous recombination, which results in the generation of a fully replicative adenovirus (RCA), a situation that compromises the purity of the viral preparation. Our laboratory has previously patented an A549 cell line expressing the E1 region and producing RCA-free recombinant adenovirus (BMAdE1). However, the replication of E1-deleted adenovirus in BMAdE1 cells was sub-optimal, in the range of 15-30% the level obtained in 293 cells. The work done in this thesis establishes that the low level of E1B-55K could be responsible for the lower productivity of BMAdE1 cells. Thus, we have derived new clones following lentiviral transduction in order to increase E1B-55K expression. Western blot confirmed that some clones expressed more E1B-55K than BMAdE1, and this correlated with a more robust replication of a recombinant adenovirus in those clones. This newly optimized BMAdE1 cell line was adapted to serum-free suspension culture.

Die Gentherapie hämatopoetischer Stammzellen (HSCs) besitzt das Potenzial, verschiedene erbliche, nur symptomatisch behandelbare, Erkrankungen dauerhaft zu heilen. Die Mehrheit der aktuell angewandten Verfahren dazu, basiert auf der Isolation von hämatopoetischen Stammzellen, der ex vivo Modifikation dieser Zellen durch retrovirale Vektoren und der Reinfusion der modifizierten Zellen in den immunsupprimierten Patienten. Dieser Ansatz ist mit einer Reihe von Nachteilen verbunden, unter anderem einem teilweisen Verlust des Rekonstitutionsvermögens der Stammzellen nach ex vivo Kultur oder der Gefahr der Transformation durch Integration des retroviralen Vektorgenoms. Darüber hinaus sind aktuelle Gentherapieansätze mit hohen Kosten und großem logistischem Aufwand verbunden, was den Zugang zu diesen Behandlungen für potentielle Patienten stark einschränkt. Die vorliegende Arbeit verfolgt einen neuen Ansatz zur Gentherapie von HSCs, der auf der Mobilisierung von Stammzellen aus dem Knochenmark in den peripheren Blutstrom und der Transduktion dieser Stammzellen mit adenoviralen Vektoren basiert. Hierbei codieren die Vektoren sowohl ein Transgen als auch eine Integrationsmaschinerie. Der erste Teil der Arbeit belegt in einem humanen CD46-transgenen Mausmodell, dass adenovirale Vektoren der ersten Generation in der Lage sind, mobilisierte HSCs im Blut zu transduzieren und dass es den so transduzierten Stammzellen möglich ist, zurück ins Knochenmark zu migrieren und dort das Transgen zu exprimieren. Allerdings wurde im Verlauf von zwei Wochen ein Rückgang der Transgenexpression beobachtet. Um dies zu umgehen, wurde ein adenovirales Vektorsystem der dritten Generation genutzt, das eine hochaktive Sleeping Beauty Transposase, zum Zweck der Transgenintegration, codiert. Dieses System ermöglichte die stabile Genmodifikation mobilisierter hämatopoetischer Stammzellen nach intravenöser Injektion. Die Expression des Transgens konnte über längere Zeitspannen (bis 12 Wochen) beobachtet werden. Die modifizeirten Stammzellen waren darüber hinaus in der Lage, genmodifizierte Kolonien in vitro zu bilden und das hämatopoetische System letal bestrahlter Mäuse nach Knochenmarkstransplantation zu rekonstituieren. Es wurde somit gezeigt, dass HSCs nach in vivo Modifikation weiterhin funktional waren. / The gene therapy of hematopoietic stem cells holds the potential for curative treatment of several otherwise incurable inherited diseases. The majority of current gene therapy treatments relies on the collection of hematopoietic stem cells, their ex vivo modification with retroviral vectors and their transplantation into a myeloconditioned patient. This approach entails several disadvantages, including a reduction of stem cell engraftment potential after ex vivo culture and the potential danger of integrational mutagenesis. In addition, the high costs and complex logistics of this approach limit the access of patients to gene therapeutic regimens. This work explores an alternative approach to hematopoietic stem cell (HSC) gene therapy, termed stem cell in vivo transduction. This approach is based on the mobilization of HSCs from the bone marrow into the peripheral blood and the transduction of the stem cells with adenoviral vectors delivering a transgene as well as a transgene integration machinery. In the first part of this work, it was shown that first-generation adenoviral vectors could be used for the transduction of mobilized HSCs in the periphery of human CD46-transgenic mice. Further, the transduced HSCs were able to home back to the bone marrow and express the transgene. However, over the course of 14 days, a loss of transgene expression in HSCs was observed. To ameliorate these shortcomings, helper-dependent adenoviral vectors encoding a hyperactive Sleeping Beauty transposase for transgene integration were used for stable gene modification of hematopoietic stem cells following intravenous vector administration in mobilized human CD46-transgenic mice. Using this improved vector platform, gene marking of bone marrow HSCs could be observed for extended periods of time (up to 12 weeks). Further, the functionality of the modified HSCs was demonstrated both in colony-forming progenitor assays as well as through the transplantation of gene-modified HSCs into lethally irradiated recipients. Transplantation of modified HSCsled to long-term multi-lineage reconstitution showing that gene-modified stem cells were fully functional. Subsequently the safety of systemic vector administration in mobilized hosts as well as of the Sleeping Beauty-mediated transgene integration was assessed in human CD46- transgenic mice. Lastly, the stem cell in vivo transduction approach was employed in NOG mice transplanted with human CD34+ cells, as well as in Macaca nemestrina non-human primates.

Die autosomal-dominant vererbte Familiäre Hypercholesterinämie ist durch eine exzessive Erhöhung der LDL-Serumcholesterinspiegel gekennzeichnet und bedingt aufgrund einer prämaturen Atherosklerose den frühzeitigen Tod der Patienten. Da ursächlich ein defekter LDL-Rezeptor (LDL-R) zugrundeliegt, der durch Mutationen im Bereich des LDL-R-Gens hervorgerufen wird, kommt der Gentherapie als potentieller Behandlungsmöglichkeit ein besonderer Stellenwert zu. Diese Arbeit untersuchte den Einfluß einer Virusdosiseskalation auf Cholesterinsenkung und Langzeitexpression im adenoviral vermittelten LDL-R-Gentransferversuch im Kaninchenmodell. Hierfür wurden 7 Watanabe Heritable Hyperlipidemic Kaninchen, welche an einer vergleichbaren kongenitalen Hypercholesterinämie durch einen LDL-R-Defekt leiden, mit unterschiedlichen Dosierungen eines Adenovirus des Serotyps 5 therapiert, der die Gensequenz für den humanen LDL-R enthielt. Vor und nach Therapie wurden Bestimmungen der Serumcholesterinkonzentrationen und LDL-Stoffwechselkinetiken mit 125I-LDL sowie semiquantitative szintigraphische Auswertungen durch 111In-LDL-Scans durchgeführt. Hierbei mußte festgestellt werden, dass die adenoviral vermittelte transgene Expression des LDL-R durch die Bestimmung des Serumcholesterins nicht korrekt wiedergegeben wird. Denn zum einen konnte bei der Bestimmung des Serumcholesterins ein dosisabhängiger Effekt beobachtet werden, dieser zeigte sich bei den Stoffwechselkinetiken mit 125I-LDL und bei den Scanuntersuchungen mit 111-In-LDL jedoch nicht. Zum anderen kam es innerhalb von 12-18 Tagen nach Gentransfer zu einem Wiedererreichen der Serumcholesterinausgangswerte, wohingegen die in vivo-Stoffwechselkinetiken eine erhöhte Abbaurate radiomarkierter LDL und die Szintigraphie eine LDL-R-Expression über die gesamte Dauer des Experimentes von 120 Tagen belegten. / Familial hypercholesterolemia is an autosomal dominantly inherited disease characterized by an exzessive elevation of serum LDL cholesterol which leads to premature atherosclerosis and an early death of the patients. As the reason is a defective LDL receptor (LDLR) caused by mutations in the gene encoding LDLR, gene therapy plays an increasingly important role as a treatment possibility. This paper examined the influence of an escalation of the virus dose on the cholestorol reduction and long-term expression in the adenovirally mediated LDLR gene therapy experiment using a rabbit animal model. To facilitate this 7 Watanabe Heritable Hyperlipidemic rabbits, suffering from an equivalent congenital hypercholesterolemia due to a LDLR defect, were treated with different doses of a serotype 5 adenovirus which contained the gene sequence of the human LDLR. Pre and post gene therapy measurements of the serum cholesterol levels and kinetics of LDL metabolism with 125I-LDL were performed, as well as semiquantitative scintigraphic analysis of 111In-LDL scans. The finding was that the adenovirally mediated transgene expression of the LDLR was not correctly reflected by the measurement of the serum cholesterol levels. This was because of a dose dependant effect concerning the measurements of the serum LDL cholesterol levels, which did not appear regarding the kinetics of LDL metabolism with 125I-LDL and the scans with 111In-LDL. Moreover, the serum cholesterol levels reached their initial value within 12-18 days post gene transfer whilst the in vivo-kinetics of LDL metabolism showed an increased catabolic rate of radiolabeled LDL and the scintigraphy indicated a LDLR expression for the whole period of the experiment lasting 120 days.

Tumoren entwickeln während einer Chemotherapie häufig Resistenzen gegen strukturell und funktionell unabhängige Zytostatika - ein Phänomen, das als Multidrug-Resistenz (MDR) bezeichnet wird und die Hauptursache für das Scheitern einer Chemotherapie ist. Die klassische MDR ist mit einer Überexpression des ABC-Transporters MDR1/P-gp assoziiert. Der vorliegende gentherapeutische Ansatz beinhaltet eine selektiv gegen MDR1/P-gp gerichtete und vor allem effiziente Strategie zur Überwindung des MDR-Phänotyps humaner Tumorzellen. Basierend auf der Integration verschiedener anti-MDR1 shRNA Expressionskassetten in adenovirale Gentherapievektoren, konnte mit Hilfe der RNA-Interferenz Technologie (RNAi) die MDR1/P-gp Expression selektiv inhibiert werden. Mittels des hoch effizienten Adenovirus Ad5U6/MDR-C wurde die MDR1 mRNA- sowie Protein-Expression soweit reprimiert, dass eine vollständige Aufhebung der biologischen Aktivität der Effluxpumpe MDR1/P-gp und eine Reversion des Resistenz Phänotyps gegenüber den typischen MDR1/P-g-Substraten Daunorubicin (87 % in EPP85-181RDB bzw. 66 % in EPG85-257RDB) sowie Vincristin (96 % bzw. 82 %) resultierte. Zudem wurde gezeigt, dass E1-deletierte und damit replikationsinkompetente Adenoviren in multidrug-resistenten Tumorzellen replizieren können. Damit wirkt Ad5U6/MDR-C in MDR-Tumorzellen onkolytisch. Zwar konnte die Adenovirusreplikation mit dem DNA-Synthese-Hemmer Hydroxyurea (HU) zu 94 % inhibiert werden, die anti-MDR1 Effizienz von Ad5U6/MDR-C wurde dennoch erhöht (+5 % in HeLaRDB, +12 % in EPG85-257RDB), was für eine erfolgreiche und niedrig dosierte Ad-Gentherapie multidrug-resistenter Tumoren in Kombination mit HU ausgenutzt werden kann. Außerdem wurde der entscheidende Einfluss des regulatorischen Proteins YB-1 auf die selektive Replikation von Ad5U6/MDR-C in MDR1/P-gp überexprimierenden Tumorzellen gezeigt. Eine 90 %ige Inhibition von YB-1 bedingt eine Hemmung der Adenovirusreplikation um 70 % und damit eine verringerte Effizienz der RNAi-vermittelten Inhibition von MDR1/P-gp um 40 %. Mit diesem gentherapeutischen Ansatz können die Effekte der YB-1-abhängigen und der die Zelllyse bedingenden Adenovirusreplikation sowie der anti-MDR1 shRNA vermittelten Chemosensitivierung kombiniert und zu einer verbesserten Eliminierung von MDR-Tumorzellen führen. / Simultaneous resistance of cancer cells to multiple cytotoxic drugs, multidrug resistance (MDR), is the major limitation to the successful chemotherapeutic treatment of disseminated neoplasms. The ‘classical’ MDR phenotype is conferred by MDR1/P-glycoprotein (MDR1/P-gp) that is expressed in almost 50% of human cancers. Recent developments in the use of small interfering RNAs for specific inhibition of gene expression have highlighted their potential use as therapeutic agents. DNA cassettes encoding RNA polymerase III promoter-driven siRNA-like short hairpin RNAs (shRNAs) allow long-term expression of therapeutic RNAs in targeted cells. A variety of viral vectors have been used to deliver such cassettes to mammalian cells. In this study, the construction of different adenoviruses for anti- MDR1/P-gp shRNA delivery in different human multidrug-resistant cancer cells was investigated. It could be demonstrated that MDR1/P-gp mRNA and protein expression could be completely inhibited by adenoviral delivery of anti-MDR1/P-gp shRNAs. This down regulation in mRNA and protein expression was accompanied by a complete inhibition of the pump activity of MDR1/P-gp and a reversal of the multidrug-resistant phenotype. Moreover, it could be demonstrated that MDR-tumour cells facilitate adenoviral replication of originally E1- and E3-deleted and thus replication deficient adenoviral vectors through stable relocation of the fundamental regulatory factor YB-1 to the nucleus. To analyse the impact of YB-1 on adenoviral replication, two specific in vitro MDR models were used which stably trigger YB-1 posttranscriptional gene-silencing via the RNA interference (RNAi) pathway, i.e. the MDR cell line EPG85-257RDB well as its drug-sensitive counterpart EPG85-257P. The YB-1 gene-silencing effects of 90 % were accompanied by a reduction of adenoviral gene expression of 70 %. In conclusion, the data demonstrate that an highly efficient adenoviral delivery of shRNAs can chemosensitise human cancer cells and that YB-1 is involved in the regulation of adenoviral gene expression of originally replication deficient Ad-vectors in MDR cancer cells.

A presença de Ad com competência para replicar (RCA, replication-competent adenovirus) nas preparações é um dos maiores problemas para a produção de Ad em larga escala. RCAs são gerados pela recombinação entre seqüência do vetor e seqüência homóloga do gene E1 presente nas células helper. Objetivo: desenvolver uma nova linhagem auxiliar para produção de Ad livre de RCA - LEY79 - derivada da linhagem de retinoblastoma humano Y79, tratando-se da primeira linhagem empacotadora de adenovírus com inativação mutacional da proteína supressora de tumor pRb, que crescem em suspensão. Células Y79 foram infectadas com o retrovírus pCLDE1A/E1BSN, selecionadas com G418. A eficiência de produção de AdeGFP na linhagem LEY79 foi testada e comparada com a HEK293A. Células Y79 foram adaptadas em meio livre de soro. Esperamos com a linhagem LEY79SF inovar no campo de processos para a produção de Ad recombinante. / The presence of Ad with the ability to replicate (RCA, replication-competent adenovirus) in preparations is a major problem in the large-scale production of Ad. RCAs are generated by recombination between the vector sequence and sequence of the homologous gene in E1 helper cells. Objective: To develop a new helper cell line for the production of RCA-free Ad., called LEY79, derived from the Y79 of human retinoblastoma line, the first line Packer adenovirus with mutational inactivation of the tumor suppressor protein pRb, which are adapted to grow in suspension. Y79 cells were infected with the retrovirus pCLDE1A/E1BSN, selected with G418. The efficiency of production of AdeGFP in the LEY79 was tested and compared with the HEK293A. Y79 cells were adapted to grow in serum-free medium. We hope that use of the the LEY79SF cell line will promote innovation in the processing and production of recombinant Ad.

Les adénovirus humains (HAdVs) provoquent généralement une infection bénigne chez l'hôte sain. En revanche, chez les patients immunodéprimés et immunocompétents, ils peuvent causer des infections sévères à létales. Les vecteurs HAdVs sont couramment utilisés dans les domaines de la thérapie génique et de la vaccination. L'immunité pré-existante de l’hôte protège généralement contre les infections de type sauvage mais peut entraîner des effets indésirables lors du relargage des virus tel que l’induction de processus inflammatoire locale ou général. Après l'infection, l'inflammation va principalement entraîner le recrutement de cellules dendritiques (DCs), de monocytes et de neutrophiles. Les DCs ont la capacité unique de présenter l'antigène et d’activer les cellules T, qui, par la suite, aideront les cellules B à produire des anticorps. En plus de leurs activités phagocytaires, des peptides antimicrobiens dérivés des neutrophiles (AMPs) jouent un rôle central dans l'immunité innée. Les AMPs peuvent neutraliser les microbes infectieux et / ou activer différents types de cellules immunitaires. Dans ce contexte, nous avons étudié l'interaction ex vivo entre le facteur hôte (anticorps anti-HADV et AMPs) contre les HAdVs dans les DCs ainsi que le rôle des DCs activés indirectement (indir-DCs) lors de la réponse immunitaire. Nous avons caractérisé le profil des cytokines et des chimiokines sécrétées par les DCs stimulées par différents HAdVs, AMPs et les combinaisons qui en découlent. Enfin, nous avons constaté que l’opsonisation d’HAdV5 par les IgG accroît la capacité de capture antigénique des MoDCs (cellules dendritiques dérivées de monocytes) et induit la mort cellulaire par pyroptose. Je me suis donc concentrée sur les caractéristiques et la fonction des indir-DCs dans l’immunité contre les HAdVs. Afin de mieux comprendre les propriétés et les phénotypes des indir-DCs et DCs activés directement (dir-DCs), nous avons caractérisé leurs profils de maturation, les facteurs influençant cette maturation, et leur capacité fonctionnelle de recruter les leucocytes. Ainsi nous avons pu mettre en évidence que les dir-DCs empêchent le recrutement leucocytaire tandis que les indir-DCs favorisent la migration des monocytes. L’ensemble de ces données contribue à comprendre comment l'immunité pré-existante contre les HAdVs peut impacter l’efficacité des traitements contre les maladies HAdVs ainsi que la conception de vaccins. / Human adenoviruses (HAdV) generally cause mild infection in healthy host, but in immunocompromised and immunocompetent patients, they cause severe on lethal infections. HAdV vector are also commonly used for gene transfer and vaccination. We know that pre-existing immunity can protect from wild type infection and cause adverse effects during vector delivery including local and system inflammation. Following HAdV infection on vector use, inflammation leads to the recruitment of dendritic cells (DCs), monocyte and neutrophils. DCs have the unique ability to present antigens and activate T cells, that subsequently aid B cells to produce antibodies. In addition to their phagocytic activities, neutrophil-derived antimicrobial peptides (AMPs) play a central role in innate immunity. AMPs can kill invading microbes and/or activate various cell types. Here I studied the ex vivo interaction between host factor (anti-HAdV antibodies and AMPs) to HAdV in DCs and the role of indirect-activated DC (indir-DCs) in immune response. I characterized the profile of cytokines and chemokines of DC stimulated with different HAdV, AMPs and their combination. We recently found that IgG-oposonization of HAdV5 increase the update by MoDCs (monoctyes-derived dendritic cells) and induced pyroptotic cell death. I therefore focused on the characteristic and function of indir-DCs in anti-HAdV immunity. To better understand the properties and phenotypes of indir-DCs and direct-activated DCs (dir-DCs), we characterize their maturation profile, the factors influencing their maturation, and the functional ability to recruit leukocyte. We found that dir-DC prevent leucocyte recruitment while indir-DC increases monocyte migration. These data contribute to understand how the pre-existing immunity to HAdV impacts treatment for HAdV diseases and vaccine design.

Der Coxsackie- und Adenovirus Rezeptor (CAR) ist als Bestandteil von Tight Junctions (TJ) an interzellulären Adhäsionsprozessen beteiligt und scheint eine wichtige Rolle in der Karzinogenese zu spielen. Diese ist jedoch insbesondere bei Entstehung von Darmkrebs weitgehend unklar. Ziel der Arbeit war es daher, die funktionelle Bedeutung, mögliche Interaktionspartner sowie die Expressionsregulation von CAR im kolorektalen Karzinom zu analysieren. In den Zelllinien CaCo2, Colo205, DLD1, HCT116, HT29, SW480 und T84 konnte die Expression von CAR (mRNA und Protein) nachgewiesen werden. Nach stabiler CAR-Überexpression durch Transfektion von CARcDNA in DLD1, HCT116 und SW480 wurde das Zellwachstum gehemmt und eine Abnahme von Migration und Invasion induziert. Eine stabile CAR-Inhibition nach Transfektion von CARsiRNA führte in diesen Zelllinien zum Anstieg der Proliferation sowie zu verstärkter Migrations- und Invasionsaktivität, die in DLD1 mit morphologischen Änderungen einhergingen. Eine Genexpressionsanalyse der Zelllinie DLD1 mit CAR-Inhibition identifizierte α-Catenin als das am stärksten regulierte Gen. Obwohl keine direkte Interaktion beider Proteine detektiert werden konnte, führte eine stabile Re-Expression von α-Catenin in DLD1 mit stabiler CAR-Inhibition zu einer deutlichen Reduktion von Proliferation, Migration und Invasion sowie zu einem Rückgang der zellmorphologischen Änderungen. Um den Einfluss von Differenzierung auf die Regulation der CAR-Expression zu untersuchen, erfolgte eine Behandlung aller Zelllinien mit Natriumbutyrat. Dies führte in fünf der sieben Zelllinien zu einer Aktivierung des CAR-Promotors sowie zu einer gesteigerten Expression und Immunoreaktivität von CAR an der Zelloberfläche. Die Zelllinie CaCo2 zeigte nach spontaner Differenzierung durch 21-tägiges Wachstum post Konfluenz ebenfalls eine verstärkte CAR-mRNA-Expression sowie eine erhöhte CAR-Präsenz an der Zelloberfläche. Die gewonnenen Daten konnten die funktionelle Bedeutung von CAR für die Kolonkarzinogenese sowie den Einfluss von α-Catenin auf diese Funktion deutlich machen. Es wurde gezeigt, dass die Expressionsregulation sowie die subzelluläre Verteilung von CAR durch den zellulären Differenzierungsstatus beeinflusst werden kann. / The Coxsackie and Adenovirus Receptor (CAR) is a transmembrane compound of the tight junctions in polarized epithelial cells mediating cellular adhesion. CAR was suggested to play a functional role in the development of epithelial malignomas but detailed knowledge is still lacking, especially for the colorectal carcinoma. Therefore, the functional impact and regulation of CAR expression in human colorectal carcinoma cell models were investigated. CAR protein and mRNA was detectable in the cell lines CaCo2, Colo205, DLD1, HCT116, HT29, SW480 and T84. Stable CAR over expression by transfection of CARcDNA in DLD1, HCT116 and SW480 led to reduced proliferation in vitro and in vivo. Also reduced migration and invasion were observed. Stable CAR inhibition by transfection of CARsiRNA in the same cell lines resulted in increased migration and invasion. In DLD1 morphological changes were found after CAR inhibition. Differential gene expression was detected in DLD1 cells with stable CAR inhibition revealing an 18-fold decrease in α-Catenin gene expression. Loss of α-Catenin was obtained on protein level, too. Although no direct interaction between CAR and α-Catenin could be proven ectopic re-expression of α-Catenin in DLD1 with CAR inhibition reversed the determined functional and morphological effects of a CAR knock down. Then, the impact of differentiation on regulation of CAR expression was investigated. Sodium butyrate treatment induced differentiation in all cell lines (determined by alkaline phosphatase activity), which was paralleled by an increase of CAR immunoreactivity at the plasma membrane in all cell lines but CaCo2. However, CAR protein and mRNA expression, as well as CAR gene promoter activity increased in 5 cell lines only, whereas in SW480 and CaCo2 a down regulation was observed. Spontaneous differentiation of CaCo2 after a growth period of 21 days post confluence resulted in up regulation of CAR mRNA expression as well as increased CAR presence at the plasma membrane. The data suggest that CAR plays a crucial role in the carcinogenesis of colorectal carcinoma which could be influenced by α-Catenin interaction. Differentiation determines the regulation of CAR expression and the subcellular distribution of CAR in colon cancer cells.

No description available.